The long noncoding RNA MEG3 is downregulated and inversely associated with vegf levels in osteoarthritis

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Su, Wei ^a   Xie, Wen ^b   Shang, Qingkun ^c   Su, Bing ^d  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b Luoyang Orthopedic Hospital   (China)

^c UNIVERSITY AT BUFFALO   (United States)

^d Biomedical Research Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LONG UNTRANSLATED RNA; MESSENGER RNA; PROTEIN MEG3; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN 189; MEG3 NON-CODING RNA, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; ARTICULAR CARTILAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; INFLAMMATION; KNEE OSTEOARTHRITIS; MALE; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UPREGULATION; BIOSYNTHESIS; CHINA; CHONDROCYTE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); OSTEOARTHRITIS; PATHOLOGY; PATHOPHYSIOLOGY;

AGED; CHINA; CHONDROCYTES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OSTEOARTHRITIS; RNA, LONG NONCODING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84930941492     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/356893     Document Type: Article

References (21)

1. J.W. J. Bijlsma, F. Berenbaum, and F. P. J. G. Lafeber, Osteoarthritis: an update with relevance for clinical practice, The Lancet, vol. 377, no. 9783, pp. 2115-2126, 2011.
2. Y.Henrotin, L. Pesesse, and C. Lambert, Targeting the synovial angiogenesis as a novel treatment approach to osteoarthritis, Therapeutic Advances in Musculoskeletal Disease, vol. 6, no. 1, pp. 20-34, 2014.
3. L. Lipovich, R. Johnson, and C.-Y. Lin, MacroRNA underdogs in a microRNA world: evolutionary, regulatory, and biomedical significance of mammalian long non-protein-coding RNA, Biochimica et Biophysica Acta: Gene Regulatory Mechanisms, vol. 1799, no. 9, pp. 597-615, 2010.
4. C. A. Brosnan and O. Voinnet, The long and the short of noncoding RNAs, Current Opinion in Cell Biology, vol. 21, no. 3, pp. 416-425, 2009.
5. J. S. Mattick, Non-coding RNAs: the architects of eukaryotic complexity, EMBO Reports, vol. 2, no. 11, pp. 986-991, 2001.
6. S. Miyaki and H. Asahara, Macro view of microRNA function in osteoarthritis, Nature Reviews Rheumatology, vol. 8, no. 9, pp. 543-552, 2012.
7. C. P. Ponting, P. L. Oliver, andW. Reik, Evolutionandfunctions of long noncodingRNAs, Cell, vol. 136, no.4,pp. 629-641, 2009.
8. M. Fu, G. Huang, Z. Zhang et al., Expression profile of long noncoding RNAs in cartilage fromknee osteoarthritis patients, Osteoarthritis and Cartilage, vol. 23, no. 3, pp. 423-432, 2015.
9. L. Benetatos, G. Vartholomatos, and E. Hatzimichael, MEG3 imprinted gene contribution in tumorigenesis, International Journal of Cancer, vol. 129, no. 4, pp. 773-779, 2011.
10. F. E. Gordon, C. L. Nutt, P. Cheunsuchon et al., Increased expression of angiogenic genes in the brains of mouse Meg3-null embryos, Endocrinology, vol. 151, no. 6, pp. 2443-2452, 2010.
11. P. Wang, Z. Ren, and P. Sun, Overexpression of the long noncoding RNA MEG3 impairs in vitro glioma cell proliferation, Journal of Cellular Biochemistry, vol. 113, no. 6, pp. 1868-1874, 2012.
12. S. Wellmann, T. Taube, K. Paal et al., Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology, Clinical Chemistry, vol. 47, no. 4, pp. 654-660, 2001.
13. T. Pufe, W. Petersen, B. Tillmann, and R. Mentlein, The splice variants VEGF121 and VEGF189 of the angiogenic peptide vascular endothelial growth factor are expressed in osteoarthritic cartilage, Arthritis and Rheumatism, vol. 44, no. 5, pp. 1082-1088, 2001.
14. D. I. R. Holmes and I. Zachary, The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease, Genome Biology, vol. 6, no. 2, article 209, 2005.
15. X. Zhang, K. Rice, Y.Wang et al., Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoformstructure, expression, and functions, Endocrinology, vol. 151, no. 3, pp. 939-947, 2010.
16. P. I. Mapp and D. A.Walsh, Mechanisms and targets of angiogenesis and nerve growth in osteoarthritis, Nature Reviews Rheumatology, vol. 8, no. 7, pp. 390-398, 2012.
17. H.-P. Gerber, T. H. Vu, A. M. Ryan, J. Kowalski, Z. Werb, and N. Ferrara, VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation, Nature Medicine, vol. 5, no. 6, pp. 623-628, 1999.
18. J. Harper and M. Klagsbrun, Cartilage to bone-angiogenesis leads the way, Nature Medicine, vol. 5, no. 6, pp. 617-618, 1999.
19. Y. Zhou, Y. Zhong, Y. Wang et al., Activation of p53 by MEG3 non-coding RNA, The Journal of Biological Chemistry, vol. 282, no. 34, pp. 24731-24742, 2007.
20. Y.Zhou, X. Zhang, andA.Klibanski, MEG3 noncodingRNA: a tumor suppressor, Journal of Molecular Endocrinology, vol. 48, no. 3, pp. R45-R53, 2012.
21. S. Pal, K. Datta, and D. Mukhopadhyay, Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma, Cancer Research, vol. 61, no. 18, pp. 6952-6957, 2001.